SLC16A1 and breast carcinoma: Akin to BACH1, MCT1 is a known prognosis marker for breast cancer [18,19], and the inhibition of MCT1 using AZD3965 is currently under investigation in clinical trials to be applied as a targeted cancer therapy [22].